| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
22,487 |
21,071 |
$2.20M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
19,538 |
18,756 |
$1.31M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
6,619 |
6,584 |
$670K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
5,992 |
5,923 |
$564K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
10,514 |
10,397 |
$376K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
363 |
165 |
$220K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
2,957 |
2,927 |
$185K |
| 99215 |
Prolong outpt/office vis |
1,207 |
1,153 |
$146K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
8,424 |
8,139 |
$145K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
963 |
954 |
$138K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
3,457 |
3,410 |
$124K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
558 |
547 |
$105K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
3,704 |
3,660 |
$18K |
| 81002 |
|
6,485 |
6,316 |
$12K |
| 99072 |
|
3,649 |
3,361 |
$11K |
| 87806 |
|
348 |
347 |
$10K |
| 36415 |
Collection of venous blood by venipuncture |
2,484 |
2,398 |
$9K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
454 |
450 |
$7K |
| 81025 |
|
707 |
700 |
$6K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
304 |
300 |
$4K |
| 86318 |
|
226 |
225 |
$4K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
51 |
51 |
$3K |
| 87808 |
|
197 |
195 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
246 |
240 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,126 |
1,080 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
60 |
59 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
60 |
59 |
$2K |
| 87634 |
|
24 |
24 |
$2K |
| 95117 |
|
98 |
39 |
$1K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
117 |
116 |
$1K |
| 87899 |
|
67 |
67 |
$1K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
154 |
148 |
$831.46 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
504 |
482 |
$815.91 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
58 |
58 |
$525.92 |
| 36416 |
|
533 |
522 |
$367.03 |
| 93000 |
|
25 |
25 |
$362.90 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
13 |
13 |
$239.80 |
| 87905 |
|
14 |
14 |
$161.65 |
| J7626 |
Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg |
45 |
43 |
$62.76 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
199 |
193 |
$7.96 |